跳到主要內容

臺灣博碩士論文加值系統

(3.231.230.177) 您好!臺灣時間:2021/08/02 10:05
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:林韋齊
研究生(外文):Wei-Chi Lin
論文名稱:探討GlyoxalaseI在人類胃上皮細胞癌中過度表現及其臨床病理意義
論文名稱(外文):Over-expression of Glyoxalase I in human Gastric Carcinoma and its Clinicopathological Significance
指導教授:林光輝林光輝引用關係
指導教授(外文):Kwang-Huei Lin
學位類別:碩士
校院名稱:長庚大學
系所名稱:基礎醫學研究所
學門:醫藥衛生學門
學類:醫學學類
論文種類:學術論文
論文出版年:2007
畢業學年度:95
語文別:中文
論文頁數:44
中文關鍵詞:胃癌
外文關鍵詞:Glyoxalse 1Gsatric cancer
相關次數:
  • 被引用被引用:1
  • 點閱點閱:242
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
Gastric cancer is the fifth leading cause of cancer-related death in Taiwan. Identification of gastric cancer related factor is essential to increase patient survival. Glyoxalase 1 ( GLO1 ) was identified using 2-DE combined with MALDI TOF/TOF MS. Glyoxalase I (GLO1), also named lactoylglutathione lyase, belongs to Glyoxalase system. The glyoxalase system includes two enzymes, GLO1 and GLO2, and can detoxify the bi-products of metabolism into material which would not hurt the cell. GLO1 is the first enzyme that work in this detoxifying process. The expression of GLO1 mRNA was up-regulated in tumor tissues (compared with adjacent non-tumor tissues) of about 67.6% gastric patients. The GLO1 expression in tumor tissues was averagely increased by 3.11-fold compared with that expressed by adjacent noncancerous mucosa. The expression of GLO1 protein was also identified by western blot and IHC. The clinic-pathological correlation of Glyoxalase I was valuated. Elevated GLO1 expression was strongly correlated with distant metastasis and tumor type. In order to understand the relationship between GLO1 over-expression and gastric cancer, GLO1 over-expression stable clones were established. Experimental results indicate that over-expression of GLO1 can enhance anti-cancer drugs, camptothecin and etoposide, induced cell death. These results indicate that GLO1 over-expression in tumor tissue may correlate with the situation of metastasis, gastric cancer type, and anti-cancer drugs
treatment.
指導教授推薦書
口試委員會審定書
授權書………………………………………………………………………………………………… iii
誌謝……………………………………………………………………………………………………… iv
中文摘要………………………………………………………………………………………………… v
英文摘要………………………………………………………………………………………………… vi
目錄 ……………………………………………………………………………………………………… vii
I. 簡介……………………………………………………………………………… 1
I-1 Glyoxalase I的生理功能………………………… 2
I-2 Methylglyoxal…………………………………………… 3
I-3 Cancer和Glyoxalase I的關係……………… 4
II. 材料與方法………………………………………………………………… 5
II-1 細胞株……………………………………………………………………… 5
II-2 組織蛋白質及RNA抽取………………………………………… 5
II-3 定量反轉錄聚合酶連鎖反應……………………………………… 6
II-4 質體製作…………………………………………………………………… 7
II-5 西方點墨法………………………………………………………………… 8
II-6 建立GLO1穩定過度表現細胞株…………………………… 8
II-7 GLO1活性試驗……………………………………………………… 9
II-8 多株抗體製作…………………………………………………………… 9
II-9 抗體競爭試驗………………………………………………………… 10
II-10 抗體純化…………………………………………………………………………… 11
II-11 抗癌藥物敏感度試驗………………………………………………………… 12
II-12 免疫組織染色法………………………………………………………………… 12
III. 結果…………………………………………………………………………………………. 13
III-1 二維電泳結果……………………………………………………………… 14
III-2 比較癌組織和正常組織中GLO1 mRNA的表現量……… 14
III-3 分析Q-PCR和病人的臨床病理之間的關係…………………… 15
III-4 製作GLO1穩定過度表現細胞株…………………………………… 15
III-5 過度表現的GLO1蛋白確實具有應有的酵素活性…………… 15
III-6 製作專一性針對GST-GLO1重組蛋白的多株抗體……… 16
III-7 比較GLO1蛋白質在病人組織中的表現量…………………… 17
III-8免疫組織染色…………………………………………………………………… 18
III-9 過度表現GLO1的細胞株對於抗癌藥物較敏感………………… 18

IV. 討論………………………………………………………………………………………………………. 19
V. 參考文獻…………………………………………………………………………………………………… 22
VI. 附錄…………………………………………………………………………………………………. 27
1.Leizhen Zheng, Liwei Wang, Jaffer Ajani, and Keping Xie. Molecular basis of gastric cancer development and progression.
2004, Gastric Cancer, 7, 61-77.
2.Chi-De Chen, Chia-Siu Wang, Ya-Hui Huang, Kun-Yi Chien, Ying Liang, Wei-Jan Chen, and Kwang-Huei Lin. Over-expression of CLIC1 in human gastric carcinoma and its clinicpathological
significance. 2007, Proteomics, 7, 155-167.
3.Wen-Chang Lin, Hsiao-Wei Kao, Daniel Robinson, Hsing-Jien Kung, Chew-Wun Wu, and Hua-Chien Chen. Tyrosine kinases and
gastric cancer. 2000, Oncogene, 19, 5680-5689.
4.Wataru Yasui, Naohide Oue, Phyu Phyu Aung, Shunji Matsumura, Mariko Shutoh, and Hirofumi Nakayama. Molecular-pathological prognostic factors of gastric cancer: a review . 2005, Gastric
Cancer, 8, 86-94.
5.Paul J. Thornalley. The glyoxalase system in health and disease.
1993, Molec. Aspects Me, 14, 87-371.
6.P.J. Thornalley. Glyoxalase I-structure, function and a critical role in the enzymatic defence against glycation. 2003,
Biochemical Society Transations, 31, 1343-1348.
7.Abordo EA, Minhas HS, and Thornalley PJ. Accumulation of alpha-oxoaldehydes during oxidative stress: a role in cytotoxicity.
1999, Biochem. Pharmacol., 58, 641-648.
8.Thornalley PJ. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. 1998, Chem Biol Interact., 111-112, 137-151.
9.Moritsugu Shinohara, P.J. Thornalley, Ida Giardino, Paul Beisswenger, Suzanne R. Thorpe, Joelle Onorato, and Michael Brownlee. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. 1998, J. Clin. Invest., 101,
1142-1147.
10.Thornallley, P.J, Edwards, L.G., Kang, Y.,Wyatt, C.,Davies, N., Ladan, M.J. and Double, J. Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. 1996,
Biochemical Pharmacology, 51, 1365-1372.
11.Rosamund E. Allen, Theodore W. C. Lo and Paul J. Thornalley. A simplified method for the purification of human red blood cell glyoxalase. I. Characteristics, immunoblotting, and inhibitor
studies. 1993, J. Protein Chem., 12, 111-119.
12.Miklo´s Pe´ter Kalapos. Methylglyoxal in living organisms Chemistry, biochemistry, toxicology and biological Implications.
1999, Toxicology Letters, 110, 145–175.
13.S. Agalou, N. Ahmed, A. Dawnay and P.J. Thornalley. Removal of advanced glycation end products in clinical renal failure by peritoneal dialysis and haemodialysis. 2003, Biochem. Soc. Trans.,
31, 1394–1396.
14.Franky Van Herreweghe, Jianqiang Mao, Frank W. R. Chaplen, John Grooten, Kris Gevaert, Joel Vandekerckhove, and Katis Vancompernolle. Tumor necrosis factor-induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxalal-drived AGE. 2002, PNAS, 99, 949-954.
15.Frank W. R. Chaplen, William E. Fahl, and Douglas C. Cameron. Evidence of high levels of methylglyoxal in cultured Chinese hamster ovary cells. 1998, Proc.Natl. Acad. Sci. USA, 95,
5533–5538.
16.P.J. Thornalley1. The enzymatic defence against glycation in health, disease and therapeutics: a symposium to examine the
concept. 2003, Biochem. Soc. Trans., 31, 1341–1342.
17.Ravichandran Ramasamy, Shi Fang Yan, and Ann Marie Schmidt.
Methylglyoxal comes of AGE. 2006, Cell, 124, 258-260.
18.Hiroshi akamoto, Tetsuo Mashima, Kazuo Yamamoto, and Takashi Tsuruo. Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification. 2002, The
Journal of Biologcal Chemistry, 277, 45770-45775.
19.Ravichandran Ramasamy, Susan J. Vannucci, Shirley Shi Du Yan, Kevan Herold, Shi Fang Yan, and Ann Marie Schmidt1. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. 2005,
Glycobiology , 15, 16R–28R.
20.Sylvie Poggioli, Hilaire Bakala and Bertrand Friguet. Age-related increase of protein glycation in peripheral blood lymphocytes is restricted to preferential target proteins. 2002, Exp. Gerontol., 37,
1207–1215.
21.Claire L. Price, Patrick S. Sharp, Margaret E. North, Sandra J. Rainbow, and Stella C. Knight. Advanced glycation end products modulate the maturation and function of peripheral blood
dendritic cells. 2004, Diabetes, 53, 1452-1458.
22.Jonathan P. Godbou, James Pesavento, Matthew E. Hartman, Scott R. Manson, and Gregory G. Freund. Methylglyoxal enhances cisplatin-induced cytotoxicity by activating protein kinase Cδ. 2002, The Journal of Biological Chemistry, 277, 2554-2561.
23.Sulabha RanganathanS, Eileen S. Walsh, Andrew K. Godwing, and Kenneth D. Tew. Cloning and characterization of human colon glyoxalase-I. 1993, The Journal of Biological Chemistry, 268,
5661-5667.
24.Davidson SD, Cherry JP, Choudhury MS, Tazaki H, Mallouh C, Konno S. Glyoxalase I activity in human prostate cancer: a potential marker and importance in chemotherapy. 1999, J Uro,
161(2):690-691.
25.Antonio Rulli, Luciano Carli, Rita Romani, Tiziano Baroni, Elvio Giovannini, Gabriella Rosi, and Vincenzo Talesa. Expression of glyoxalase I and II in normal and breast cancer tissues. 2001,
BreastCancer Research and Treatment,66, 67–72.
26.Antogenelli C, Baldracchini F, Talesa VN, Costantini E, Zucchi A, Mearini E. Overexpression of glyoxalase system enzymes inhuman
kidney tumor. 2006, Cancer J, 12, 222-228.
27.Hiroshi Sakamoto, Tetsuo Mashima, Shigeo Sato, Yuichi Hashioto, Takao Yamori, and Takashi Tsuruo. Selective Activation of Apoptosis Program by S-p-bromobenzylglutathione Cyclopentyl Diester in Glyoxalase I-overexpressing Human Lung Cancer Cells.
2001, Clinical Cancer Research, 7, 2513-2518.
28.Hiroshi Sakamoto, Tetsuo Mashima, Atsuo Kizaki, Shingo Dan, Yuichi Hashimoto, Mikihiko Naito, and Takasi Tsuruo. Glyoxlase I in involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. 2000, BLOOD, 95, 3214-3218.
29.DaoHai Zhang, Lee Kian Tai, Lee Lee Wong, Lily Lily Chiu, Sunil K. Sethi, and Evelyn S. C. Koay. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER/neu-2 positive breast cancer.2005.
Molecular & Cellular Proteomics, 4, 1686-1696.
30.Hai-Yan Song A Yin-Kun Liu A Ju-Tao Feng Jie-Feng Cui A Zhi Dai A Li-Jun Zhang A Jiu-Xian Feng Hua-Li Shen A Zhao-You Tang. Proteomic analysis on metastasis-associated proteins of human hepatocellular carcinoma tissues. 2006, J Cancer Res Clin
Oncol, 132: 92–98.
31.Hiroshi Sakamoto, Tetsuo Mashima, Shigeo Sato, Yuichi Hashimoto, Takao Yamori, and Takashi Tsuruo. Selective Activation of Apoptosis Program by S-p-bromobenzylglutathione Cyclopentyl Diester in Glyoxalase I-overexpressing Human Lung Cancer Cell. 2001, Clinical Cancer Reasearch, 7, 2513-2518.
32.Yves Pommier. Topoisomerase I inhibitors:camptothecins and
beyond. 2006, Nat Rev Cancer, 6, 789-802.
33.K.R. Hande. Etoposide:Four decades of development of a topoisomerase II inhibitor. 1998, European Journal of Cancer, 34,
1514-1521.
34.Yarden, Y., and Sliwkowski, M. X. Untangling the ErbB signaling
network. 2001, Nat. Rev. Mol. Cell. Biol., 2, 127–137.
35.Isola, J., Chu, L., DeVries, S., Matsumura, K., Chew, K., Ljung, B. M., and Waldman, F. M. Genetic alterations in ERBB2-amplified breast carcinomas. 1999, Clin. Cancer Res., 5, 4140–4145.
36.Zhang, D.-H., Salto-Tellez, M., Do, E., Putti, T. C., and Koay, E. S. C. Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. 2003, Hum. Pathol., 34, 362–368.
37.Citri, A., Skaria, K. B., and Yarden, Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. 2003, Exp. Cell Res., 284, 54–65.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
1. 林富士,〈疾病與「修道」:中國早期道士「修道」因緣考釋之一〉,收入《漢學研究》,第19卷第1期,2001,頁137-165。
2. 李豐楙,〈丹道與濟度:道教修行的實踐之道〉,收入《宗教哲學季刊》第6卷第2期,2000.6,臺北:中華民國宗教哲學研究社,頁123-135。
3. 李豐楙,〈嵇康養生思想之研究〉,收入《靜宜學報》第2期,臺中:靜宜文理學院,1979.8,頁37-66。
4. 宋光宇,〈在理教發展簡史〉,收入《思與言》第15卷第1期,1977.5,頁1-17。
5. 江達智,〈全真教初期掌教考〉,收入《漢學研究》第16卷第1期,1998.6,頁111-123。
6. 莊宏誼,〈道教靈修築基:靜坐原理與方法〉,收入《輔仁宗教研究》第6輯(2002冬),臺北:輔仁大學出版社,頁135-163。
7. 莊宏誼,〈北宋道士張伯端法脈及其金丹思想〉,收入《輔仁宗教研究》第7輯(2003.6),臺北:輔仁大學出版社,頁119-151。
8. 陳俊民,〈論全真道及其內丹長生思想之演變〉,收入《漢學研究》第16卷第2
9. 鄭素春,〈金元全真道丘長春真人行誼及其宗派發展〉,收入《丹道文化‧丘處機
10. 鄭素春,〈道教生命教育學理之建構〉收入《輔仁宗教研究》第8輯(2003冬),臺北:輔仁大學出版社,頁61-98。
11. 鄭素春,〈元代全真道長春宗派的南傳:以金志陽法脈為主的研究〉,收入《丹道研究》創刊號,臺北:丹道文化出版公司,2006.7,頁134-186。
12. 鄭懌、曾右任,〈地磁變化與養生時辰〉,收入《科學月刊》第28卷第3期,1997.3,頁218-223。
13. 鄺蘭夫,〈內丹學南宗張伯端之理論分析〉,收入《東海哲學研究集刊》,1997第4期,頁13-45
14. 4. 李源泉(1990)。「臺灣農田水利會組織與經營之研究」。臺灣水利,第38卷,第4期,1-39。
15. 5. 李源泉(1990)。「臺灣農田水利會組織與經營之研究」。臺灣水利。第38卷,第4期,頁1-39。